The Arcview Group will honor “The Father of Cannabis Research” with a Lifetime Achievement Award and a $10,000 research grant in their first annual cannabis awards presentation at the Arcview Investor Forum: The Evolution of Cannabis: 2020 in New York on Thursday, October 3, 2019, at 7:00 p.m.
Raphael Mechoulam’s contribution to our understanding and ability to use the cannabis plant for positive benefits is immeasurable. He is being recognized for his cutting-edge cannabis research and breakthrough discovery of THC, one of at least 113 cannabinoids identified in the cannabis plant.
Arcview will be preserving and continuing to honor the invaluable work and contributions by Raphael Mechoulam’s work by naming future recipients of this award the “Arcview Raphael Mechoulam Lifetime Achievement Award.”
“Cannabis research has never been more critical to the future of our industry, especially as the federal government begins processing dozens of pending applications for the steps necessary to improve access to marijuana research,” said The Arcview Group CEO and co-founder Troy Dayton. “As the first person to synthesize THC, identify the endocannabinoid system and illustrate the medicinal properties of cannabis, no one is more deserving than Raphael of our Lifetime Achievement Award. We can’t wait to see what he uncovers next.”
About Rafael Mechoulam
Mechoulam is the first person responsible for isolating cannabinoids, including Tetrahydrocannabinol (THC) and anandamide, which led to the breakthrough discoveries of the endocannabinoid system and the total synthesis of cannabinoids in the cannabis plant. His laboratory has worked on the chemistry, pharmacology and clinical effects of natural products, including cannabis, for more than 50 years. Mechoulam’s current research focuses on the numerous anandamide-like compounds in mammals, many of which are involved in basic biological reactions, such as bone formation, blood vessel relaxation, head trauma and addiction in addition and the development of novel cannabinoids and anandamide-like compounds as pharmaceutical drugs.